Aurobindo Pharma gets warning letter from USFDA for API facility

Aurobindo Pharma on Friday said it has received a warning letter from the US health regulator for its Hyderabad-based Unit I, an API (active pharmaceutical ingredient) manufacturing facility.
Category: News